Global Plasma-derived Factor VIII Market
As the global economy mends, the 2021 growth of Plasma-derived Factor VIII will have significant ... Read More
As the global economy mends, the 2021 growth of Recombinant Factor VIII will have significant change from previous year. According to our (LP Information) latest study, the global Recombinant Factor VIII market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Recombinant Factor VIII market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Recombinant Factor VIII market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Recombinant Factor VIII market, reaching US$ million by the year 2028. As for the Europe Recombinant Factor VIII landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Recombinant Factor VIII players cover Takeda, Bayer, CSL, and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Factor VIII market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
200IU
250IU
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
NovoNordisk
As the global economy mends, the 2021 growth of Plasma-derived Factor VIII will have significant ... Read More
As the global economy mends, the 2021 growth of Immune Globulins will have significant change fro ... Read More
As the global economy mends, the 2021 growth of Immune Globulin Intravenous will have significant ... Read More
As the global economy mends, the 2021 growth of Human Immune Globulin Intravenous will have signi ... Read More